Physician profile
James Marshall
NPI 1710955034
$1,279.16
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $35.65 · 2021: $235 · 2022: $165 · 2023: $215 · 2024: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $191.20 | 2023-2024 | Gemtesa, Orgovyx |
| Pfizer INC. | $96.61 | 2019-2024 | |
| Rochester Medical Corporation | $96.16 | 2019-2021 | |
| Astellas Pharma US INC | $90.06 | 2019-2022 | |
| Myovant Sciences INC. | $87.80 | 2021-2022 | |
| Urovant Sciences INC | $87.48 | 2021-2022 | |
| Halozyme INC | $80.35 | 2023 | |
| Procept Biorobotics Corporation | $69.74 | 2024 | Aquabeam System |
| Antares Pharma, INC. | $68.82 | 2019-2024 | Xyosted |
| Laborie Medical Technologies Corp. | $46.87 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $46.80 | 2021-2024 | Prolaris |
| Coloplast Corp | $46.61 | 2021-2024 | Speedicath |
| Endo Pharmaceuticals INC. | $31.45 | 2019 | |
| Urogen Pharma, INC. | $31.15 | 2024 | |
| 180 Medical, INC. | $27.55 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $25.91 | 2019 | |
| Hollister Incorporated | $25.53 | 2024 | Vapro Plus Pocket |
| Abc Home Medical Supply, INC. | $25.53 | 2024 | |
| Olympus America INC. | $24.70 | 2023 | Uretero-Reno Videoscope |
| Duchesnay USA Incorporated | $18.03 | 2019 | |
| Boston Scientific Corporation | $16.01 | 2019 | |
| Genentech USA, INC. | $15.94 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.